Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVNS AVANOS MEDICAL	$10.83 +0.7%	$11.82	$9.30 ▼ $25.36	$502.51M	1.12	535,422 shs	454,733 shs
BBNX Beta Bionics	$16.11 +6.7%	$15.52	$8.89 ▼ $24.50	$700.30M	N/A	518,916 shs	259,945 shs
EMBC Embecta	$13.72 -1.6%	$10.41	$9.20 ▼ $21.48	$798.91M	1.08	606,431 shs	297,624 shs
LNSR LENSAR	$12.58 -1.4%	$12.88	$3.80 ▼ $17.31	$150.02M	0.5	132,025 shs	33,390 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVNS AVANOS MEDICAL	-0.66%	+4.35%	-9.40%	-15.76%	-52.44%
BBNX Beta Bionics	+6.19%	-0.66%	+17.69%	+9.66%	+1,509,999,900.00%
EMBC Embecta	+4.65%	+41.24%	+34.43%	+19.55%	-5.94%
LNSR LENSAR	-1.24%	-2.07%	-1.09%	-9.57%	+211.22%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVNS AVANOS MEDICAL	1.684 of 5 stars	0.0	3.0	0.0	1.0	1.7	2.5
BBNX Beta Bionics	2.7979 of 5 stars	4.4	0.0	0.0	3.3	0.8	0.0
EMBC Embecta	4.7434 of 5 stars	3.2	3.0	3.3	3.1	3.3	3.8
LNSR LENSAR	0.6241 of 5 stars	2.0	1.0	0.0	1.0	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVNS AVANOS MEDICAL	0.00	N/A	N/A	N/A
BBNX Beta Bionics	2.75	Moderate Buy	$22.56	40.01% Upside
EMBC Embecta	2.33	Hold	$19.00	38.53% Upside
LNSR LENSAR	2.00	Hold	$15.00	19.24% Upside

Current Analyst Ratings Breakdown

Latest LNSR, EMBC, BBNX, and AVNS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2025	BBNX Beta Bionics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$18.00 ➝ $21.00
7/30/2025	BBNX Beta Bionics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral ➝ Neutral	$15.00 ➝ $17.00
7/16/2025	EMBC Embecta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$13.00 ➝ $12.00
6/16/2025	BBNX Beta Bionics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$26.00
6/12/2025	BBNX Beta Bionics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$30.00
5/30/2025	BBNX Beta Bionics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$16.00
5/30/2025	BBNX Beta Bionics	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$20.00
5/23/2025	EMBC Embecta	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$25.00
5/23/2025	EMBC Embecta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$15.00 ➝ $13.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVNS AVANOS MEDICAL	$687.80M	0.73	$11.90 per share	0.91	$16.73 per share	0.65
BBNX Beta Bionics	$78.02M	8.98	N/A	N/A	$6.94 per share	2.32
EMBC Embecta	$1.10B	0.73	$3.44 per share	3.99	($11.45) per share	-1.20
LNSR LENSAR	$58.36M	2.57	N/A	N/A	($1.93) per share	-6.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVNS AVANOS MEDICAL	-$392.10M	-$10.07	N/A	6.26	N/A	-66.89%	6.16%	4.57%	10/29/2025 (Estimated)
BBNX Beta Bionics	-$54.76M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
EMBC Embecta	$78.30M	$1.43	9.55	4.47	0.74	7.58%	-23.40%	14.46%	N/A
LNSR LENSAR	-$31.40M	-$4.21	N/A	∞	N/A	-84.49%	-737.30%	-72.60%	8/14/2025 (Estimated)

Latest LNSR, EMBC, BBNX, and AVNS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/8/2025	Q3 2025	EMBC Embecta	$0.7720	$1.12	+$0.3480	$0.78	$278.15 million	$295.50 million
8/7/2025	Q2 2025	LNSR LENSAR	-$0.0750	-$0.15	-$0.0750	-$0.15	$16.55 million	$11.36 million
8/5/2025	Q2 2025	AVNS AVANOS MEDICAL	$0.18	$0.17	-$0.01	-$1.66	$165.50 million	$175.00 million
7/29/2025	Q2 2025	BBNX Beta Bionics	-$0.51	-$0.39	+$0.12	-$0.39	$19.73 million	$23.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVNS AVANOS MEDICAL	N/A	N/A	N/A	N/A	N/A
BBNX Beta Bionics	N/A	N/A	N/A	N/A	N/A
EMBC Embecta	$0.60	4.37%	N/A	41.96%	N/A
LNSR LENSAR	N/A	N/A	N/A	N/A	N/A

Latest LNSR, EMBC, BBNX, and AVNS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/6/2025	EMBC Embecta	quarterly	$0.15	5.79%	8/29/2025	8/29/2025	9/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVNS AVANOS MEDICAL	0.12	2.64	1.58
BBNX Beta Bionics	N/A	14.68	13.79
EMBC Embecta	N/A	2.47	1.78
LNSR LENSAR	N/A	1.52	0.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVNS AVANOS MEDICAL	95.17%
BBNX Beta Bionics	N/A
EMBC Embecta	93.83%
LNSR LENSAR	40.15%

Insider Ownership

Company	Insider Ownership
AVNS AVANOS MEDICAL	2.64%
BBNX Beta Bionics	N/A
EMBC Embecta	0.42%
LNSR LENSAR	38.52%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVNS AVANOS MEDICAL	2,227	46.40 million	45.18 million	Optionable
BBNX Beta Bionics	294	43.47 million	N/A	N/A
EMBC Embecta	2,100	58.49 million	58.24 million	Optionable
LNSR LENSAR	110	11.94 million	7.34 million	Optionable

LNSR, EMBC, BBNX, and AVNS Headlines

Recent News About These Companies

LENSAR Reports Second Quarter 2025 Results and Provides Business Update

August 7, 2025 | globenewswire.com

LENSAR (LNSR) Projected to Post Earnings on Thursday

August 7, 2025 | marketbeat.com

32,000 Shares in LENSAR, Inc. (NASDAQ:LNSR) Acquired by Tabor Asset Management LP

July 22, 2025 | marketbeat.com

Tabor Asset Management LP Takes Position in LENSAR, Inc. (NASDAQ:LNSR)

July 18, 2025 | marketbeat.com

LENSAR, Inc. Grants 660 Restricted Stock Units to New Non-Executive Employees as Inducement for Employment - Nasdaq

July 3, 2025 | nasdaq.com

LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - Morningstar

July 3, 2025 | morningstar.comM

LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 1, 2025 | globenewswire.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SVT, LNSR, ICAD, SSBK on Behalf of Shareholders

June 11, 2025 | morningstar.comM

$TOCKHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of SVT, SSBK, LNSR, iCAD to Act

June 10, 2025 | morningstar.comM

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, SWTX, ICAD, SSBK on Behalf of Shareholders

June 5, 2025 | morningstar.comM

LENSAR, Inc. Grants 3,090 Restricted Stock Units to New Employees as Inducement for Employment

June 4, 2025 | nasdaq.com

$HAREHOLDER INVESTIGATION: The M&A Class Action Firm Is Investigating the Merger: SSBK, LNSR, iCAD and BSGM

June 3, 2025 | morningstar.comM

LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR

June 3, 2025 | businesswire.com

LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2025 | globenewswire.com

LENSAR Reports First Quarter 2025 Results and Provides Business Update

May 8, 2025 | globenewswire.com

Is LENSAR (LNSR) a Deeply Undervalued Stock?

April 10, 2025 | msn.com

LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR

March 26, 2025 | businesswire.com

Lensar downgraded to Hold from Buy at Lake Street

March 26, 2025 | markets.businessinsider.com

ALC Stock Rises Following the Merger Agreement With LENSAR

March 25, 2025 | zacks.com

Lake Street Downgrades LENSAR (LNSR)

March 25, 2025 | msn.com

Shareholder Alert: The Ademi Firm Investigates Whether LENSAR, Inc. is Obtaining a Fair Price for Its Public Shareholders

March 24, 2025 | tmcnet.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNSR, EMBC, BBNX, and AVNS Company Descriptions

AVANOS MEDICAL NYSE:AVNS

$10.82 +0.08 (+0.70%)

As of 02:54 PM Eastern

Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.

Beta Bionics NASDAQ:BBNX

$16.11 +1.01 (+6.69%)

As of 02:33 PM Eastern

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.

Embecta NASDAQ:EMBC

$13.72 -0.23 (-1.61%)

As of 02:53 PM Eastern

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.

LENSAR NASDAQ:LNSR

$12.58 -0.18 (-1.41%)

As of 02:50 PM Eastern

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time